New clinical trial to tackle hard-to-treat leukaemia
- 3 December 2015
A new clinical trial at Oxford's Churchill Hospital plans to study the safety of a new experimental drug to treat a form of leukaemia, called Acute Myeloid Leukaemia (AML).
Acute myeloid leukaemia is the most common aggressive blood cancer and there are about 2,200 new cases in the UK each year. It can be hard to treat, especially in patients over 65 years of age, and is often fatal within a year of diagnosis. Therefore, there is an urgent need for more effective therapies.
Read more (Oxford University Hospitals NHS Foundation Trust website)